FDA Regulatory Capture
OngoingThe revolving door between FDA and pharmaceutical companies ensures industry-friendly regulation. Former pharma executives approve drugs from their old companies, then return to industry jobs. The FDA is funded 75% by the companies it regulates through user fees.
Evidence:
- 75% of FDA drug review budget from pharma fees
- Revolving door - executives become regulators and vice versa
- Fast-tracked approvals with inadequate testing
- Suppressed adverse event data
- Off-label promotion ignored or lightly fined